These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 17006915

  • 1. Impaired 11 beta-hydroxysteroid dehydrogenase contributes to renal sodium avidity in cirrhosis: hypothesis or fact?
    Frey FJ.
    Hepatology; 2006 Oct; 44(4):795-801. PubMed ID: 17006915
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system.
    Mihailidou AS, Funder JW.
    Steroids; 2005 Oct; 70(5-7):347-51. PubMed ID: 15862816
    [Abstract] [Full Text] [Related]

  • 8. 11 beta-Hydroxysteroid dehydrogenase: a link between the dysregulation of cortisol metabolism and hypertension.
    Donovan SJ.
    Br J Biomed Sci; 1999 Oct; 56(3):215-25. PubMed ID: 10824333
    [Abstract] [Full Text] [Related]

  • 9. Chenodeoxycholic acid and deoxycholic acid inhibit 11 beta-hydroxysteroid dehydrogenase type 2 and cause cortisol-induced transcriptional activation of the mineralocorticoid receptor.
    Stauffer AT, Rochat MK, Dick B, Frey FJ, Odermatt A.
    J Biol Chem; 2002 Jul 19; 277(29):26286-92. PubMed ID: 12015312
    [Abstract] [Full Text] [Related]

  • 10. Reduced activity of 11beta-hydroxysteroid dehydrogenase type 2 is not responsible for sodium retention in nephrotic rats.
    Bistrup C, Thiesson HC, Jensen BL, Skøtt O.
    Acta Physiol Scand; 2005 Jun 19; 184(2):161-9. PubMed ID: 15916676
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Deoxycorticosterone inactivation by AKR1C3 in human mineralocorticoid target tissues.
    Sharma KK, Lindqvist A, Zhou XJ, Auchus RJ, Penning TM, Andersson S.
    Mol Cell Endocrinol; 2006 Mar 27; 248(1-2):79-86. PubMed ID: 16337083
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mineralocorticoid receptors: emerging complexity and functional diversity.
    Odermatt A, Atanasov AG.
    Steroids; 2009 Feb 27; 74(2):163-71. PubMed ID: 19022273
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Interactions of mineralocorticoids and glucocorticoids in epithelial target tissues revisited.
    Morris DJ, Latif SA, Brem AS.
    Steroids; 2009 Jan 27; 74(1):1-6. PubMed ID: 19013186
    [Abstract] [Full Text] [Related]

  • 20. The promiscuous receptor: a case for the guardian enzyme.
    Funder JW.
    Cardiovasc Res; 1995 Aug 27; 30(2):177-80. PubMed ID: 7585802
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.